The Intercept Pharmaceuticals, Inc. (ICPT) Receives $181.31 Average PT from Brokerages

The Intercept Pharmaceuticals, Inc. (ICPT) Receives $181.31 Average PT from Brokerages

ICPT has been the subject of a number of research reports. Oppenheimer Holdings, Inc. reissued an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, April 12th. Wedbush reissued an “outperform” rating and issued a $224.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, March 17th. Credit Suisse Group increased their price target on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a research note on Friday, May 5th. Laidlaw raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price target for the company in a research note on Friday, May 5th. Finally, Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 1st.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $180.14.

Shares of Intercept Pharmaceuticals (ICPT) opened at 121.76 on Wednesday. The firm’s 50-day moving average price is $115.92 and its 200-day moving average price is $113.69. Intercept Pharmaceuticals has a one year low of $96.63 and a one year high of $177.93. The firm’s market capitalization is $3.05 billion. Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) EPS for the quarter, beating the consensus estimate of ($4.27) by $0.66. The firm had revenue of $21 million during the quarter, compared to the consensus estimate of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The company’s quarterly revenue was up 4566.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($5.17) earnings per share. On average, equities analysts forecast that Intercept Pharmaceuticals will post ($14.50) earnings per share for the current year.

In other news, insider Lisa Bright sold 389 shares of the stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $115.00, for a total transaction of $44,735.00. Following the sale, the insider now owns 22,925 shares in the company, valued at $2,636,375. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CMO David Shapiro sold 1,117 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the sale, the chief marketing officer now owns 46,582 shares in the company, valued at approximately $5,225,568.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,016 shares of company stock worth $452,624. Corporate insiders own 4.50% of the company’s stock. A number of large investors have recently modified their holdings of the company. Teachers Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 2.0% in the third quarter. Teachers Advisors LLC now owns 14,071 shares of the biopharmaceutical company’s stock valued at $2,316,000 after buying an additional 279 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Intercept Pharmaceuticals by 9.5% in the third quarter. Pacer Advisors Inc. now owns 1,384 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 120 shares in the last quarter. Marco Investment Management LLC bought a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at about $247,000. Chartwell Investment Partners LLC bought a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at about $10,181,000. Finally, ING Groep NV bought a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at about $2,120,000. Institutional investors own 84.39% of the company’s stock.

In other news, insider Lisa Bright sold 389 shares of the stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $115.00, for a total transaction of $44,735.00. Following the sale, the insider now owns 22,925 shares in the company, valued at $2,636,375. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CMO David Shapiro sold 1,117 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the sale, the chief marketing officer now owns 46,582 shares in the company, valued at approximately $5,225,568.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,016 shares of company stock worth $452,624. Corporate insiders own 4.50% of the company’s stock. About Intercept Pharmaceuticals

Related posts

Leave a Comment